1. This article discusses the screening of rosmarinic acid from Salvia miltiorrhizae as a potential active component acting on TRPC1, a target for treating cardiac injury.
2. The TCM Systems Pharmacology Database and Analysis Platform was used to retrieve Salvia miltiorrhiza compounds for preliminary screening, and surface plasmon resonance (SPR) was used to determine the affinity of the optimal compound to TRPC1 protein.
3. Rosmarinic acid (RosA) was obtained based on the molecular docking scoring function, and it had a high binding affinity to TRPC1 protein (KD value = 1.27 µM).
This article is generally reliable and trustworthy in its reporting of the research conducted on screening rosmarinic acid from Salvia miltiorrhizae as a potential active component acting on TRPC1, a target for treating cardiac injury. The authors provide detailed information about their methods, including using the TCM Systems Pharmacology Database and Analysis Platform to retrieve Salvia miltiorrhiza compounds for preliminary screening and surface plasmon resonance (SPR) to determine the affinity of the optimal compound to TRPC1 protein. They also provide evidence for their claims by citing relevant studies in their discussion section. Additionally, they note possible risks associated with their findings in their conclusion section.
The only potential bias that could be identified in this article is that it does not present both sides equally; while it provides evidence for its claims, it does not explore any counterarguments or alternative explanations for its findings. However, this is understandable given that this is a research paper rather than an opinion piece or debate article.